When blood sugar spikes and crashes, it can cause feelings of fatigue, irritability, and mood swings. Keeping blood sugar ...

Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today ...

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find ...

About BriaCell Therapeutics BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

In in vitro and in vivo preclinical studies, ficerafusp alfa + a KRAS-G12C inhibitor (G12Ci) was shown to be more effective than G12Ci alone, with G12Ci-resistant lung cancer cells remaining ...

Sheding Weight, not only helps you shed weight, but Mitolyn is unique as it naturally and totally enhances your health, ...

Increase in semen volume: after consuming a single dosage of Volume Pills, men might begin to experience enhanced sexual ...

FMC-220 was discovered using the Frontier™ Platform, integrating chemoproteomics, covalent fragment-based discovery, and machine learning. FMC-220 is the second potential first-in-class program to ...

Details for the poster presentation are as follows: Presentation Title: An mRNA-encoded masked IL-12 improves systemic tolerability while maintaining anti-tumor efficacy in preclinical studies Poster ...

Louvain-la-Neuve, Belgium, April 28th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA ...

TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 Annual Meeting of Shareholders on Friday, June 20, 2025, at ...

Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase ...